Illumina sues BGI in Germany for patent infringement

Illumina has filed a lawsuit against BGI subsidiary latvia MGI tech in the Düsseldorf regional court in Germany, alleging that BGI’s sequencing products and related reagents infringe a patent Illumina holds in Europe, EP 1 530 578 B1, which covers sequencing-by-synthesis chemistry.’

Illumina will not tolerate the unauthorized, infringing use of its patented technology,” Charles Dadswell, senior vice president and general counsel for Illumina, said in a statement. “We will continue to monitor the field and file patent suits where appropriate when our patents are infringed.”

The Latvia operations of MGI Tech were established to prepare the firm for instrument sales in Europe. MGI recently told GenomeWeb that the facility will become operational by the end of this year.